Ritobegron
Alternative Names: KUC 7483 BS; KUC-7483; KUC-7483 CLLatest Information Update: 02 Oct 2021
At a glance
- Originator Kissei Pharmaceutical
- Developer Boehringer Ingelheim; Kissei Pharmaceutical
- Class Acetates; Small molecules
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Overactive bladder; Urinary incontinence
Most Recent Events
- 27 Oct 2009 Phase-III clinical trials in Overactive bladder in Japan (unspecified route)
- 31 Jul 2009 Kissei Pharmaceutical completes Phase-II trials in Overactive bladder
- 06 Apr 2005 Phase-II clinical trials in Overactive bladder in United Kingdom (unspecified route)